Gilead Sciences, Inc. completed a Phase II trial of GS 9137, a novel oral HIV integrase inhibitor. The study met its primary endpoint of non-inferiority in viral load reduction in HIV-positive patients receiving 50 mg or 125 mg of GS 9137 once daily with 100 mg of ritonavir, in combination with an antiretroviral regimen compared to a comparator protease inhibitor regimen. This ongoing study is a partially-blinded, randomized, active-controlled, 48-week trial to evaluate the non-inferiority ...